JHOP - February 2021 Vol 11, No 1

Amany R. Keruakous, MD; Sarah A. Schmidt, PharmD; Marcus T. Autry, PharmD; Julia Ye, PharmD Candidate; Phoi Nguyen, PharmD Candidate; Silas Day

Original Article

Optimizing Daratumumab Infusion: Assessing the Safety and Feasibility of Omitting Preinfusion Medications and Decreasing Infusion Time

Justine Preedit, PharmD; Anya Yudchyts, PharmD, BCOP

Electrolyte Abnormalities and the Associated Risk for Atrial Fibrillation After Autologous Hematopoietic Stem-Cell Transplant

Natalie Schulze, PharmD; Kyle LaPorte, PharmD; Carol Breikreutz, PharmD, BCOP; Tobias Meissner, PhD; R. Vinod Parameswaran, MD, FRCPath, MRCP; Renju Raj, MD; Kelly McCaul, MD, ABIM, FRCPC

Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center

Sarah Maryon Hayes, PharmD, BCOP; Jeremy Whalen, PharmD, BCOP; Nick Schutz, PharmD; Joseph Levine, MD

Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan

Ekim Ekinci, PharmD, MS, BCOP; James E. Cox, PharmD, BCOP; Joe E. Ensor, PhD; Edward T. McLean, PharmD, BCOP; Carlos A. Ramos, MD; Premal D. Lulla, MD; Rammurti T. Kamble, MD; George Carrum, MD

From the Literature

Sitagliptin, a DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant

Pembrolizumab Shows Long-Term Benefits in Patients with Metastatic Colorectal Cancer and MSI-H or dMMR

FDA Updates

FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations

Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer

FDA Approves Margenza for the Treatment of Metastatic HER2-Positive Breast Cancer

Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients

Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

ASH Highlights

Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS

Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results

Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma

ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma

Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis

Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia